NovoCure Ltd. — Q1 2020 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2020; unaudited results. NovoCure develops and commercializes Tumor Treating Fields systems, including Optune for glioblastoma (GBM) and Optune Lua for malignant pleural mesothelioma (MPM). The company operates as one reportable segment.
Financial and operating performance
| Metric | Q1 2020 | Q1 2019 |
|---|---|---|
| Net revenue | $101.8 million | $73.3 million |
| Gross profit / margin | $77.3 million / 76% | $53.5 million / 73% |
| Operating income (loss) | $(3.4) million | $(6.1) million |
| Net income (loss) | $4.0 million | $(12.2) million |
| Operating cash flow | $2.0 million | $(4.3) million |
| Adjusted EBITDA (non-GAAP) | $15.1 million | $5.5 million |
Revenue increased 39%, driven by 464 additional active patients in commercial markets (18% growth) and higher revenue per patient, including improved U.S. reimbursement. At quarter-end, 3,095 GBM patients were active on therapy versus 2,631 a year earlier; Q1 prescriptions were 1,409 versus 1,310. U.S. revenue was $69.3 million, Germany $21.8 million, Japan $6.5 million, other EMEA $2.7 million, and Greater China $1.6 million.
Cost of revenue rose 24% to $24.5 million, below revenue growth, supporting the margin improvement. Operating expenses rose 35% to $80.7 million: research and clinical costs increased 48% to $25.3 million, sales and marketing 29% to $28.8 million, and general and administrative 31% to $26.6 million. Share-based compensation was $16.6 million, up from $9.6 million.
Net income included a $9.8 million income-tax benefit; the company recorded an $11.3 million benefit from U.S. net operating loss carrybacks under COVID-19-related tax legislation. Before tax, the company reported a $5.8 million loss. Thus, reported profitability depended on the tax benefit.
Liquidity, debt, and financial position
At March 31, cash and cash equivalents were $181.9 million, short-term investments $149.3 million, and restricted cash $0.8 million. Management reported $331.3 million of cash, cash equivalents, and short-term investments, sufficient for at least 12 months under its existing plan. Total liabilities were $260.5 million. Long-term loan carrying value was $149.5 million, with $150.0 million principal outstanding; interest is 9% annually, and the facility matures February 7, 2023. The loan is secured and subject to covenants, which the company said it was meeting.
Operating cash flow turned positive at $2.0 million, with working-capital movements—including increased receivables—affecting cash generation. Investing cash use was $3.1 million, primarily for property and equipment; financing provided $4.5 million, largely from option exercises. Cash, cash equivalents, and restricted cash increased $3.3 million during the quarter. Management expects research, commercial, and administrative expenses to continue rising and cautions they may outpace gross profit, potentially requiring additional capital.
Material changes, outlook, and risks
Revenue growth, improved gross margin, lower operating loss, positive operating cash flow, and positive reported net income were notable year-over-year improvements. Expenses increased substantially as the company expanded commercial activity and invested in trials. Israel added national reimbursement for Optune in newly diagnosed GBM in January 2020; Germany did so in March. The company reported approximately 263 million contracted GBM lives in the U.S., 111 million in active EMEA markets, and 127 million in Japan.
No specific financial revenue or earnings guidance was provided. Management expected clinical-trial site expansion to remain materially delayed by COVID-19, although it reported no material first-quarter financial impact and no material supply-chain impact at the filing date. It continued virtual patient and healthcare-professional engagement and monitored supply availability. Expected trial data timing: METIS in 2022; LUNAR, PANOVA-3, and INNOVATE-3 in 2023, with interim analyses in 2021; and EF-31 in 2021. INNOVATE-3 enrollment exceeded expectations, while site expansion constraints affected other trials.
COVID-19 risks include delays in patient starts, enrollment and trial operations; reduced prescriptions or reimbursement; supply and shipping disruption; and added operating costs. The filing also identifies lithium-ion battery safety risks, including potential fire, recall, litigation, or operational disruption. A separate Israeli civil claim seeking 210,000 shares was dismissed on April 3, 2020, on statute-of-limitations grounds.
Important facts for investors to verify
- Whether patient growth and improved reimbursement—particularly Medicare claims processing—sustain revenue growth and margins.
- How COVID-19 affects trial enrollment, expected data timelines, new patient starts, and ongoing patient support.
- Whether the $331.3 million liquidity balance remains adequate as operating expenses and clinical investment rise.
- The extent to which reported net income reflects the one-time tax benefit, and the persistence of operating cash generation.
- Debt service, 9% interest cost, 2023 maturity, security, and any prepayment restrictions or premiums.
- Progress on Optune Lua access and reimbursement, new-market expansion, and product battery safety controls.